Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 660Carcinoma, Non-Small-Cell Lung 454Prostatic Neoplasms 384Neoplasms 376Lung Neoplasms 261Multiple Myeloma 246Colorectal Neoplasms 231Neoplasm Metastasis 214Melanoma 202Leukemia, Myeloid, Acute 165Ovarian Neoplasms 163Pancreatic Neoplasms 155Carcinoma, Renal Cell 141Squamous Cell Carcinoma of Head and Neck 137Lymphoma 134Brain Neoplasms 132Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 123Lymphoma, Non-Hodgkin 123Carcinoma, Hepatocellular 117Head and Neck Neoplasms 114Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 107Stomach Neoplasms 106Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Uterine Cervical Neoplasms 100Hematologic Neoplasms 99Lymphoma, Follicular 95Sarcoma 93

Interventions

bazedoxifene 1Estrogens, Conjugated (USP) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Risk Reduction Behavior × 1 year × Clear all
NCT04821141 2025-10-29

Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

University of Kansas Medical Center

Phase 2 Active not recruiting
120 enrolled
Breast

Breast Neoplasms, Hot Flashes, Risk Reduction Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡